Why the study?
Are plasma ET-1 levels elevated in NIDDM patients with or without complications compared to healthy subjects?
Are plasma ET-1 levels elevated in NIDDM patients with or without complications compared to healthy subjects?
Plasma ET-1 levels do not appear to be elevated in NIDDM patients or act as a marker for diabetic complications such as angiopathy.
Answers are grounded in this paper and cite their sources.
Does not support ET-1 as a marker for NIDDM or angiopathy; leaves open its role in diabetic vascular disease.
OBJECTIVE: To measure plasma endothelin 1 (ET-1) levels in uncomplicated non-insulin-dependent diabetes mellitus (NIDDM) and investigate whether ET levels may be related to angiopathy, blood pressure, metabolic control, or duration of illness. RESEARCH DESIGN AND METHODS: Plasma levels of ET-1 were measured in 44 NIDDM patients, of whom 24 had uncomplicated diabetes, 20 had angiopathy, and 10 had hypertension. In 21 patients, the duration of illness was > 10 years, and in 23 the duration of illness was < 10 years. Serum creatinine levels, microalbuminuria, and HbA1c were determined simultaneously. Thirty normotensive healthy (nondiabetic) individuals (20 men and 10 women) served as control subjects. RESULTS: No significant statistical differences in plasma ET-1 levels were found among all diabetic patients, diabetic patients with and without angiopathy, diabetic patients with different durations of diabetes, and normal subjects. No significant correlation of plasma ET-1 with blood pressure, age, serum creatinine level, duration of diabetes, HbA1c, or diabetic complications was found. CONCLUSIONS: Plasma ET-1 levels are similar in patients with NIDDM and healthy subjects and do not seem to act as a marker of diabetic complications.
No takes yet. Share an insight, caveat, or question.
Bertello et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: